Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
BI 754091 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol. 36, no. 5_suppl (February 2018) 212-212).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ezabenlimab||BI754091|BI-754091|BI 754091||Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 93||Ezabenlimab (BI 754091) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol. 36, no. 5_suppl (February 2018) 212-212).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02952248||Phase I||Ezabenlimab||A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours||Active, not recruiting||USA | CAN||1|
|NCT03697304||Phase II||Ezabenlimab Miptenalimab||Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours.||Active, not recruiting||USA | CAN||1|
|NCT03156114||Phase I||Ezabenlimab Miptenalimab||This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.||Active, not recruiting||USA | ESP | CAN||2|